Renal

Clear Cell

No Prior Systemic Therapy

IRB# 19991
A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed By Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

IRB# 19661
EA8143: Phase 3 RandOMized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized RCC Undergoing Nephrectomy (PROSPER)

Nephrectomy Candidate

IRB# 19283
Xynomic Pazopanib +/- Abexinostate in Patients with locally advanced or Metastatic

No prior VEGF. Up to 1 prior cytokine or immune checkpoint inhibitor

Prior Systemic Therapy

Track 2: Prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4

IRB# 17027
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology

IRB# 11804
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) + Pembrol

Localized

T1b or greater (has not spread beyond the kidney)

Metastatic/locally advanced

Non-Clear Cell

IRB# 16085
S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib

Papillary Renal Carcinoma

CROSS-DISEASE TRIALS

IRB# 19992
New study coming soon

IRB# 18084
S1609 (DART)

http://www.ohsu.edu/research/rda/so/knight.php

Key

Open for Enrollment
In Development
Enrollment on Hold

New study coming soon

No Prior Systemic Therapy

No prior VEGF. Up to 1 prior cytokine or immune checkpoint inhibitor

Progression on anti-PD-1/PD-L1 mAb monotherapy or in combo w/ other therapies

http://www.ohsu.edu/research/rda/so/knight.php